Reported about 4 hours ago
Arrowhead Pharmaceuticals has partnered with Sarepta Therapeutics in a significant gene therapy deal, where Sarepta will pay $500 million upfront and invest $325 million in equity to access Arrowhead's gene silencing technologies aimed at treating rare genetic diseases impacting muscles, the central nervous system, and lungs.
Source: YAHOO